Publication|Articles|October 6, 2025
Supplements and Featured Publications
- The Role of TEVIMBRA® (tislelizumab-jsgr) in First-Line ESCC Treatment
The Role of TEVIMBRA® (tislelizumab-jsgr) in First-Line ESCC Treatment
Advertisement
This Clinical Brief was sponsored by BeOne Medicines.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
4
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
5









































